Sepracor's LUNESTA receives patent term extension from USPTO
Links shared publicly online about this topic.
- 1,522total visits
Sepracor's LUNESTA receives patent term extension from USPTO
Sepracor Inc. today announced that the United States Patent and Trademark Office has determined that U.S. Patent No. 6,444,673, which is a composition of matter patent that covers the human drug product LUNESTA® (eszopiclone), received a patent term extension under 35 U.S.C. § 156.
View full resource at news-medical.net
Tags: Insomnia Medication, Drug, Lunesta
Most Recently Shared on December 18, 2009 at 7:08 am By:
Sepracor's LUNESTA receives patent term extension from USPTO: Sepracor Inc. today announced that the United States ... http://bit.ly/5ZKwxb
Advertisement
